Bioprocess Bags Market by Type (2D Bioprocess Bags, 3D Bioprocess Bags, and Others), Workflow (Upstream Process, Downstream Process, and Process Development), Material type (Polyethylene (PE), Ethylene Vinyl Acetate (EVA), Polypropylene (PP), Polyvinyl Chloride (PVC), and Other Specialty Polymers), Sterilization methods (Gamma Irradiation, Autoclaving, Ethylene Oxide Sterilization, and Electron Beam Sterilization) and Distribution Channels (Direct Sales, Distributors & Suppliers, and Online Channels), End-users (Pharmaceutical & Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs) & Contract Research Organizations (CROs), and Academic & Research Institutes). Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles and Market Forecast, 2025 – 2035

Industry Outlook

The Bioprocess Bags Market accounted for USD 4.82 Billion in 2024 and is expected to reach USD 25.62 Billion by 2035, growing at a CAGR of around 16.4% between 2025 and 2035. The Bioprocess Bags Market is the industry that manufactures and supplies flexible containers used in biopharmaceutical manufacturing processes. Cell cultures, proteins, and vaccines are among the biological components that are stored, transported, and mixed in these bags.

They are constructed from non-contaminating materials and are intended to endure severe environments. Protein purification, cell treatment, and vaccine manufacturing all heavily rely on bioprocess bags. The market is driven by the need for biopharmaceuticals and improvements in the technology used to manufacture biologics.

Report Scope:

Market Dynamics

Growing demand for single-use technologies in biopharmaceutical production.

The Bioprocess Bags Market is growing in demand for single-use technologies, which have incorporated bioprocess bags into their designs and have widely gained acceptance within the biopharmaceutical industry as they help achieve greater flexibility and efficiency in manufacturing. Among these are lower capital investment, lower risks of cross-contamination, and relatively faster time for production. Further surges in demand for biologics such as monoclonal antibodies, vaccines, and recombinant proteins have added to this trend. A final area where single-use systems are of particular interest is the flexibility and scalability of such systems, particularly for CMOs and research institutes. Single-use technologies will increasingly be adopted as the industry moves toward a trend of greater flexibility and reduced costs in manufacturing. These technologies also provide faster turnaround times for manufacturing and offer an environmentally friendly perspective through the prevention of waste resulting from conventional stainless-steel-based equipment. Single-use systems also have streamlined natures that help scale up quicker, and changeover between runs is easier.

Enhanced efforts to minimize cross-contamination prioritizing measures to ensure safety and cleanliness.

Increased efforts to reduce cross-contamination also stimulate the growth of the Bioprocess Bags Market. Safety and hygiene continue to play an increasingly important role in biopharmaceutical production, especially with sterile products such as vaccines, monoclonal antibodies, and cell therapies. Bioprocess bags, being part of the single-use technologies, represent a point of significant advantage over reusability and contamination risks associated with reusable systems.

Their pre-sterilized nature and disposable design reduce the need for extensive cleaning and validation, streamlining operations and ensuring product purity. With stringent regulatory requirements emphasizing contamination control, the demand for bioprocess bags as a reliable, safe, and cost-effective solution continues to rise, fostering market expansion.

Concerns regarding material integrity and leachability include potential contamination, degradation, and health risks.

Material integrity and leachability concerns are notable constraints for the Bioprocess Bags Market. Potential contamination by materials of the bags, chemical degradation under extreme conditions, and migration of leachable into the final biopharmaceutical product are risks that compromise product quality and patient safety. Such risks increase production costs and regulatory complexities because they require strict testing and validation processes.

Manufacturers have difficulties ensuring that the material used will provide consistent performance in various conditions, thus slowing the introduction of bioprocess bags into highly sensitive applications. Furthermore, doubts about long-term reliability among end-users may encourage a preference for traditional stainless-steel systems, further limiting the market's growth.

Advancements in bioprocess bag materials enhance performance, supporting single-use technology growth in biopharmaceutical production.

Major growth opportunities for the Bioprocess Bags Market will arise from advancements in bioprocess bag material, including greater durability, enhanced chemical resistance, and compatibility with a wide array of biopharmaceutical applications. These advancements enable better performance and minimize the chance of contamination with simpler operations for biopharmaceutical production.

With the continued adoption of SUTs given the cost-effectiveness, scalability, and reduced need for cleaning, high-quality bioprocess bags are becoming integral. Moreover, the role they play in ensuring flexible manufacturing and complying with stringent regulatory standards further supports market demand. These factors further position the Bioprocess Bags Market to take advantage of the growing scale of biopharmaceuticals.

The biopharma industry is increasingly outsourcing to CMOs due to the growing demand for specialized manufacturing capabilities.

With the increase in outsourcing biopharmaceutical manufacturing to contract manufacturing organizations, many opportunities are opening for the Bioprocess Bags Market. Flexible and scalable solutions are often sought after by CMOs for meeting diverse client demands. For this reason, bioprocess bags emerge as the most critical single-use technologies for efficient operations, supporting low-cost production, high-speed turnaround, and conformance to regulatory requirements.

The CMOs working on highly specialized manufacturing such as cell and gene therapies or monoclonal antibodies, there is a significant requirement for high-quality, sterile, and customizable bioprocess bags. This is in line with the growth in single-use systems in biopharma and increases demand for innovative and reliable bioprocess bag solutions for a wide variety of manufacturing requirements.

Industry Experts Opinion

"Bioprocess bags have revolutionized the biopharmaceutical industry by offering scalable and flexible solutions for cell culture and media storage. Their single-use design minimizes contamination risks and streamlines production, making them a cornerstone of modern bioprocessing."

• Dr. Sophia Martinez, Bioprocess Specialist at Advanced Biotech Solutions

Segment Analysis

Based on type, the Bioprocess Bags Market is classified into 2D bioprocess, 3D bioprocesses bags, and other bags. 3D bioprocess bags are the biggest and most critical part of the Bioprocess Bags Market. This has a better capacity and a better design than others because of higher volume applications, including the storage and transportation of media, buffers, and biopharmaceuticals.

Due to their ability to retain larger volumes while maintaining product sterility, these bags are quite useful in large-volume biomanufacturing operations. The bioprocess bags' 3D construction allows for effective filling, draining, and mixing, reducing material waste and processing time. The use of 3D bioprocess bags is still common as the biopharmaceutical sector increases production to satisfy the demand for biologics and vaccines worldwide. Their market dominance is further supported by their adaptability, interoperability with cutting-edge single-use systems, and expanding application in commercial manufacturing.

Based on Workflow the Bioprocess Bags Market is classified into Upstream Process, Downstream Process, and Process Development The upstream processes are most important in the Bioprocess Bags Market. This process includes cell and microorganism cultivation to manufacture biologics, which must be maintained in controlled conditions for product quality and yield. Bioprocess bags are widely applied in media preparation, storage, and fermentation processes in upstream processes because they are sterile and disposable, thereby lowering the risk of cross-contamination.

They offer scalability and flexibility, a crucial factor for companies in the biopharma area, as demand is changing as a result of the varying demands for production. Therefore, as demand becomes more efficient and cost-effective in manufacturing processes, single-use upstream systems become the dominant sector. Furthermore, the attention on bioprocess bags upstream is heightened by the development of monoclonal antibodies and cell and gene treatments.

Regional Analysis

Advanced healthcare infrastructures, enormous biopharmaceutical research programs, and highly adopted single-use technologies in processing operations and limiting contamination risks account for the surge in North America's Bioprocess Bags Market. The demand is increasing in that region for biotherapeutic productions, vaccines, and personalized medical treatments as related to healthcare-related needs and general public health considerations. The interface between bioproduction and leading research organizations is also fueling innovation as an enabler, enhancing the readiness and scalability of novel bioprocess solutions.

North American regulatory authorities ensure that stringent quality standards are maintained regarding product reliability and safety. Moreover, technological advancement and the availability of qualified workforces have strengthened the market position of this region, and hence, this region is well-known for some bioprocessing innovations.

The Asia-Pacific region is witnessing the growth of bioprocess bags market on account of expanding biopharmaceutical and biotechnology sectors. Growth in this region is led by countries such as China, India, and Japan, which have been witnessing rising investments in the production of biologics, biosimilars, and vaccines. Cost-effectiveness, reduced risks of contamination, and operational efficiency of single-use technologies are supporting their growing demand in the region.

Government initiatives for the promotion of healthcare innovation and setting up biopharma manufacturing facilities boost the market. The rising prevalence of chronic diseases and adoption of advanced therapeutic solutions are the demand drivers. Support from regulatory bodies for sustainable and eco-friendly bioprocess solutions also resonates with the region's movement toward greener practices, enhancing the adoption of single-use bioprocess bags.

Competitive Landscape

The Bioprocess Bags Market is highly competitive, with high demand for the production of biopharmaceuticals and advancements in single-use technology. Thermo Fisher Scientific, Sartorius AG, and Merck KGaA are the principal players, they have vast bioprocessing solutions. Sartorius AG recently scaled up its production capacities in single-use manufacture, while a recent acquisition took place to enhance its life sciences portfolio via the acquisition of M Ventures.

Flexible solutions with innovations through bioprocessing GE Healthcare, Eppendorf AG. Lonza Group Ltd - advanced biomanufacturing through integration. Industry-qualified technologies, strong in robust material performance from Saint-Gobain Performance Plastics and Entegris, Inc. Fluidigm Corporation and Avantor, Inc. focused on new designs in products toward greater efficiency in the new line scale. Innovative start-ups on a rising stage-optimum Processing, Inc. for customizing. Flexbiosys Inc. This indicates that the industry is set to grow and is supported by continuous innovation and strategic investments.

Bioprocess Bags Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In December 2024, Thermo Fisher Scientific expanded its bioprocessing solution manufacturing capacity due to rising market demand.
• In November 2024, Sartorius AG introduced an advanced single-use bioprocess bag, which will help to scale up and lower the production cost.
• In October 2024, Merck KGaA launched new bioprocess bags with enhanced filtration technology to obtain higher product purity.

Report Coverage:

By Type

• 2D Bioprocess Bags
• 3D Bioprocess Bags
• Others

By Workflow

• Upstream Process
• Downstream Process
• Process Development

Material Type

• Polyethylene (PE)
• Ethylene Vinyl Acetate (EVA)
• Polypropylene (PP)
• Polyvinyl Chloride (PVC)
• Other Specialty Polymers

By Sterilization Method

• Gamma Irradiation
• Autoclaving
• Ethylene Oxide Sterilization
• Electron Beam Sterilization

By Distributional Channel

• Direct Sales
• Distributors & Suppliers
• Online Channels

By End-user

• Pharmaceutical & Biopharmaceutical Companies
• Contract Manufacturing Organizations (CMOs) & Contract Research Organizations (CROs)
• Academic & Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

•  Thermo Fisher Scientific
• Sartorius AG
• Merck KGaA
• GE Healthcare
• Eppendorf AG
• Avantor, Inc.
• Lonza Group Ltd.
• Fluidigm Corporation
• Saint-Gobain Performance Plastics Corporation
• Entegris, Inc.
• Meissner Filtration Products, Inc.
• ESI Technologies
• Biopure Technology Ltd.
• Optimum Processing Inc.
• Flexbiosys Inc.

Frequently Asked Questions (FAQs)